SynthesisAmerican journal of preventive medicine2016
Cost-Utility Analysis of Cancer Prevention, Treatment, and Control: A Systematic Review.
Synthesis in American journal of preventive medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Facilitators and Barriers to Lung Cancer Screening during Long COVID: A Global Systematic Review and Meta-Study Synthesis of Qualitative Research.International journal of environmental research and public health · 2024Pooled it
- An Exploration of the Utility and Impacts of Implementation Science Strategies by Cancer Registries for Healthcare Improvement: A Systematic Review.International journal of health policy and management · 2024Pooled it
- Systematic Review of the Cost Effectiveness of Breast Cancer Prevention, Screening, and Treatment Interventions.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Pooled it
- Scalable Telehealth Cancer Care: integrated healthy lifestyle program to live well after cancer treatment.Journal of the National Cancer Institute. Monographs · 2024Trial
- Feasibility and implementation insights from implementing the health navigator model for cancer prevention among people experiencing homelessness across Europe.European journal of public health · 2026Article
- Global burden of breast cancer and its association with red meat consumption: spatiotemporal trends, projections, and triangulation of evidence.World journal of surgical oncology · 2026Article
- Article
- Trends in cancer burden in Pakistan: a 30-year analysis from the Global Burden of Disease Study (1990-2019).Ecancermedicalscience · 2026Article
- Comparative trends in pancreatic cancer burden and risk factors in the USA and China (1990-2021): insights from GBD analysis.BMC gastroenterology · 2025Article
- Implementation of an Educational Intervention for Gastric Cancer Awareness in the General Population in CELAC and Europe: A Strategy Proposed by the LEGACy Consortium.Journal of cancer education : the official journal of the American Association for Cancer Education · 2025Article
- Validation of the Cancer-Specific Preference-Based Measure EORTC QLU-C10D against the Generic Instruments EQ-5D-5L and SF-6Dv2 in a Prospectively Collected Sample of Patients with Cancer in Austria and France.PharmacoEconomics · 2025Article
- Association between the e-healthy literacy and cancer prevention consciousness in rural China: cancer cognition acting as a mediator.Global health research and policy · 2025Article
- Challenges and future directions of gastric cancer prevention in Iran: Perspectives of the key stakeholders.Journal of education and health promotion · 2025Article
- Characterizing stakeholders in cancer primary prevention in European countries: an exploration of challenges and opportunities using a penta-helix framework.Frontiers in public health · 2025Article
- Correlation between glucose metabolism and body mass index in tumor lesions of patients with lung cancer.Discover oncology · 2024Article
- Article
- Willingness to pay for an mRNA-based anti-cancer treatment: results from a contingent valuation study in Israel.Israel journal of health policy research · 2024Article
- The burden of breast, cervical, and colon and rectum cancer in the Balkan countries, 1990-2019 and forecast to 2030.Archives of public health = Archives belges de sante publique · 2023Article
- Global trends and forecasts of breast cancer incidence and deaths.Scientific data · 2023Article
- Cancer Prevention Literacy among Different Population Subgroups: Challenges and Enabling Factors for Adopting and Complying with Cancer Prevention Recommendations.International journal of environmental research and public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
contextSubstantial innovation related to cancer prevention and treatment has occurred in recent decades. However, these innovations have often come at a significant cost. Cost-utility analysis provides a useful framework to assess if the benefits from innovation are worth the additional cost. This systematic review on published cost-utility analyses related to cancer care is from 1988 through 2013. Analyses were conducted in 2013-2015. EVIDENCE ACQUISITION: This review analyzed data from the Tufts Medical Center Cost-Effectiveness Analysis Registry (www.cearegistry.org), a comprehensive registry with detailed information on 4,339 original cost-utility analyses published in the peer-reviewed medical and economic literature through 2013. EVIDENCE SYNTHESIS: There were 721 cancer-related cost-utility analyses published from 1998 through 2013, with roughly 12% of studies focused on primary prevention and 17% focused on secondary prevention. The most often studied cancers were breast cancer (29%); colorectal cancer (11%); and prostate cancer (8%). The median reported incremental cost-effectiveness ratios (in 2014 U.S. dollars) were $25,000 for breast cancer, $24,000 for colorectal cancer, and $34,000 for prostate cancer.
conclusionsThe current evidence indicates that there are many interventions that are cost effective across cancer sites and levels of prevention. However, the results highlight the relatively small number of cancer cost-utility analyses devoted to primary prevention compared with secondary or tertiary prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.